Denali Therapeutics Inc. DNLI
At closeNov 4, 2026, 5:03 PM EST
After hours · Nov 4, 5:03 PM ET
- YTD
- +26.95%
- 1 year
- +40.48%
- Market cap
- 3.35B
- Revenue (ttm)
- 3.60M
- EPS (ttm)
- -1.72
- Shares out
- 159.85M
- Forward P/E
- -8.86
- YTD return
- +26.95%
- 1-year return
- +40.48%
- Volume
- 4.65M
- Avg volume
- 1.59M
- Open
- 21.23
- Previous close
- 19.45
- Day's range
- 19.75 – 22.19
- 52-week range
- 13.75 – 27.30
- Beta
- 1.08
- Analysts
- Strong Buy
- Price target
- 35.63 (+70.0%)
- Earnings date
- Feb 25, 2027
5D +1.26 (+6.45%)
Key statistics
- Enterprise value
- 2.44B
- PEG ratio
- 0.00
- Price / sales
- 929.63
- Price / book
- 3.23
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -268.53M
- Total cash
- 710.47M
- Total debt
- 37.69M
- Return on equity
- -54.93%
- Short % of float
- 10.21%
- 50-day average
- 20.43
- 200-day average
- 21.24
Analyst view
Consensus: strong buy
- Target (low)
- 23.00
- Target (mean)
- 35.63
- Target (high)
- 42.00
- Strong buy2
- Buy17
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -0.5675.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -0.64 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | -0.27094 | 0.37 | +0.64 | +236.56% |
| Aug 6, 2026 | Jun 30, 2026 | -0.51305 | -0.68 | -0.17 | -32.54% |
| May 7, 2026 | Mar 31, 2026 | -0.73 | -0.69 | +0.04 | +5.48% |
| Feb 26, 2026 | Dec 31, 2025 | -0.75 | -0.73 | +0.02 | +2.67% |
| Nov 6, 2025 | Sep 30, 2025 | -0.76 | -0.74 | +0.02 | +2.63% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Nov 4, 2026 | Wedbush | main | Outperform | Outperform |
| Nov 4, 2026 | BTIG | reit | Buy | Buy |
| Aug 25, 2026 | B. Riley Securities | main | Buy | Buy |
| Aug 7, 2026 | UBS | main | Buy | Buy |
| Jul 23, 2026 | Morgan Stanley | main | Overweight | Overweight |
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- denalitherapeutics.com
News
Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $42 
Wedbush Maintains Outperform on Denali Therapeutics, Raises Price Target to $24 
BTIG Reiterates Buy on Denali Therapeutics, Maintains $39 Price Target 
Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript 
Denali Therapeutics Q3 Earnings Call Highlights 
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates - UPDATE: Denali Therapeutics Q3 Adj. EPS $(0.64) Misses $(0.53) Estimate, Sales $17.778M Beat $10.657M Estimate
Denali Therapeutics Q3 2026 Earnings Call Transcript 
Denali Therapeutics Sees Q4 Sales $30.000M-$32.000M vs $22.659M Est 
Denali Therapeutics Q3 EPS $0.37 Beats $(0.59) Estimate, Sales $17.778M Beat $10.657M Estimate
Your note
Sign in to keep a note on DNLI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 2, 2026 | 0 |
| CHIN PETER SCOTT | Officer | Sale | Sep 3, 2026 | 204,538 |
| FLATLEY JAY T | Director | Stock Award(Grant) | Jun 2, 2026 | 358,941 |
| HO CAROLE | Officer | Sale | Aug 12, 2025 | 424,804 |
| KROGNES STEVE E | Director | Stock Award(Grant) | Jun 2, 2026 | 819,999 |
| SATO VICKI LEE | Director | Sale | Jan 1, 2025 | 107,976 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 10.12% | 16,178,963 | 339.11M | Jun 29, 2026 |
| Blackrock Inc. | 8.77% | 14,026,413 | 293.99M | Jun 29, 2026 |
| BAILLIE GIFFORD & CO | 7.48% | 11,960,230 | 250.69M | Jun 29, 2026 |
| State Street Corporation | 4.41% | 7,049,304 | 147.75M | Jun 29, 2026 |
| Temasek Holdings (Private) Ltd | 4.39% | 7,012,974 | 146.99M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.05% | 6,477,057 | 135.76M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 3.11% | 4,966,700 | 104.10M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.68% | 4,288,391 | 89.88M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.39% | 3,813,515 | 79.93M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.94% | 3,097,183 | 64.92M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.91% | 3,055,331 | 64.04M | Sep 29, 2026 |
| VANGUARD WORLD FUND-Vanguard U.S. Growth Fund | 1.68% | 2,681,184 | 56.20M | Aug 30, 2026 |